8/11/2019 Tabel Io Anti Hipertensi

1/1

INTERAKSI OBAT-OBAT HIPERTENSI

Interaction Efects Mechanism

Beta-Blockers AcebutololAtenolol

Betaxolol (Kerlone)Bisoprolol (Zebeta)Carteolol (Cartrol)

Esmolol (Brevibloc)Metoprolol

NadololPenbutolol (Levatol)

PindololPropranolol

SotalolTimolol

Aluminum Salts Aluminum Carbonate(Basaljel)Aluminum!"droxideAluminumP#osp#ateAttapul$ite%aolinMa

$aldrate

P#armacokinetic and p#armacolo$ic e&ects o'BETA-BC%E*S ma" be altered b" certain

A+MIN+M SATS,

T#e rate o' $astric empt"in$ ma" be decreasedleadin$ to reduced bioaailabilit" o' BETA-

BC%E*S,

Aminoglycosides Neom"cin T#e rate o' oral absorption and extrarenalelimination o' NA. ma" be increased b"

coadministration o' oral E*/T!*M/CIN base andNEM/CIN,

+nkno0n, Probable inter'erence 0it# intraluminal'at di$estion and increased biliar" excretion o'

NA.,

Amiodaone Amiodarone1 (e$ Cordarone) T#e p#armacolo$ic e&ects o' METP* andpossibl" ot#er BETA-BC%E*S eliminated b"#epatic metabolism (e$ propranolol) ma" be

increased,

.ecreased #epatic metabolism and diminis#ed 2rst-pass e&ect 0it# increased bioaailabilit" is

suspected,

Anticholinegics AtropineBelladonna

Ben3tropine (e$ Cogentin)Clidinium (Quarzan)

.ic"clomine (e$ Bentyl)4l"cop"rrolate (e$ Robinul!"osc"amine (e$Anaspaz)

Mepen3olate (Cantil)Met#scopolamine (Pamine)rp#enadrine (e$ Norfe)x"but"nin (e$ !itropan)

Proc"clidine(Kemadrin)Propant#eline1 (e$ Pro"Bant#ine)

Scopolamine ($copace)Tri#ex"p#enid"l (e$Artane)

T#e bioaailabilit" o' ATEN ma" be increasedb" t#e administration o' ANTIC!INE*4ICS,

ANTIC!INE*4ICS increase retention time o' BETA-BC%E*S in t#e stomac# t#at ma" i n turn en#ance

t#e dissolution and bioaailabilit" o' t#e dru$,

Asco!ic Acid Ascorbic Acid T#e p#armacolo$ic e&ects o' P*P*AN ma"be decreased,

Possible decreased 4I absorption o' P*P*AN

Ba!ituates Amobarbital (Amytal)Butabarbital (e$ Butisol)Mep#obarbital (%ebaral)

Pentobarbital1P#enobarbital1 (e$ $ol&oton)

Primidone (e$ %ysoline)Secobarbital ($econal)

P#armacokinetic e&ects o' certain BETA-BC%E*S ma" be reduced b" concomitant

treatment 0it# BA*BIT+*ATES,

BA*BIT+*ATES en#ance en3"me induction and#epatic 2rst-pass extraction t#at ma" reduce oral

bioaailabilit" o' certain BETA-BC%E*S,

"alcium Salts Calcium Carbonate(e$ 's"Cal )**)Calcium Citrate(Citracal)

Calcium 4lubionate(Neo"Calglucon)Calcium 4luconate

Calcium actateTricalcium P#osp#ate(Posture)

CACI+M SATS ma" alter t#e p#armacokineticparameters and decrease t#e p#armacolo$ic

e&ects o' ATEN

Impaired absorption o' ATEN in t#e 4I tractand possibl" an increase in t#e area o' olume o'

distribution,

"holestyamine C#olest"ramine1 (e$ Questran) T #e p la sma concentration o ' P*P*AN a ndmetabolite 0ere reduced 0#ic# ma" cause a

diminis#ed p#armacolo$ic e&ect,

P*P*AN appears to bind 0it# anionicexc#an$e resins 'ormin$ a complex t#at ma"

decrease absorption in t#e 4I tract,

"imetidine Cimetidine1 (e$ +agamet) P#armacolo$ic e&ects o' BETA-BC%E*Smetaboli3ed b" C/P-567 pat#0a" ma" be

increased,

CIMETI.INE ma" reduce #epatic 2rst-passextraction decrease lier blood 8o0 and in#ibit#epatic metabolism (C/P9.:) o' certain BETA-

BC%E*S,

Eythomycin Er"t#rom"cin1 (e$ ,ry"+ab) P#armacokinetic pro2le ma" be altered butt#erapeutic and p#armacolo$ic e&ects areunpredictable based on present eidence,

+ncon2rmed but possibl" because o' eradication o'intestinal 8ora-induced #"drol"sis and increasedbiliar" elimination o' NA. b" MAC*I.E

ANTIBITICS,

Ethanol Et#anol1 T#e p#armacolo$ic and t#erapeutic e&ects o' t#iscombination are di;cult to anticipate (see

discussion),

+nkno0n, Acute AC! in$estion ma" reduce$astric motilit" dela" $astric empt"in$ time and

prolon$ t#e time interal 'or P*P*AN to reac#its absorption site in t#e small intestine

Halo#eidol !aloperidol1 (e$ -aldol) P#armacolo$ic e&ects o' bot# dru$s ma" beincreased

Probable s"ner$istic p#armacolo$ic actiit",

$oo# %iuetics erapamil1 (e$ Calan) E&ects o ' bo t# dru$s ma " be increased, Possi bl e s"ner$isti c or additi e e&ects, >E*APAMIma" in#ibit oxidatie metabolism o' certain BETA-

BC%E*S,

A"E Inhi!itos Bena3epril (Lotensin)CaptoprilEnalapril

.PA, Central e&ects o'

E>.PA in Parkinson disease ma" bepotentiated b" MET!/.PA,

T#e mec#anism 'or t#e BP-lo0erin$ e&ects o'MET!/.PA and E>.PA are unkno0n,

Potentiation o' E>.PA@s central e&ects ma"result 'rom MET!/.PA in#ibition o' perip#eraldopa-decarbox"lase makin$ more E>.PA

aailable to cross t#e blood-brain barrier,